CNTA
Centessa Pharmaceuticals plcPrice
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersMIXED
No open-market sales.
- InstitutionsBEARISH
Q2 2026: 0 added (0 new), 30 trimmed or exited.
- EstimatesFLAT
Current-quarter EPS estimate −$0.392 → −$0.390 over 90 days. 2 up, 1 down in 30 days.
- Short sellersCOVERING
Short interest −37.4% to 1.61M shares. 1.2 days to cover.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | EXIT | $0.00 |
| JPMORGAN CHASE & CO | EXIT | $0.00 |
| Capital World Investors | EXIT | $0.00 |
| AMERICAN CENTURY COMPANIES INC | EXIT | $0.00 |
| FMR LLC | EXIT | $0.00 |
| MORGAN STANLEY | EXIT | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Apr 2026| Date | Firm | Rating |
|---|---|---|
| Apr 20, 2026 | Wells Fargo DOWNGRADE | Equal-Weight |
| Apr 2, 2026 | Guggenheim DOWNGRADE | Neutral |
| Apr 1, 2026 | Leerink Partners DOWNGRADE | Market Perform |
| Mar 31, 2026 | Wolfe Research DOWNGRADE | Peer Perform |
| Mar 31, 2026 | Needham DOWNGRADE | Hold |
| Feb 24, 2026 | Wolfe Research INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Stuckley Carol Director Jun 24, 2026 | TO ISSUER | 208,474 sh |
Weinhoff Gregory M Chief Business Officer Jun 24, 2026 | TO ISSUER | 65,925 sh |
HUSSAIN IQBAL J Chief Legal Officer Jun 24, 2026 | TO ISSUER | 221,559 sh |
ZBAR BRETT I W Director Jun 24, 2026 | TO ISSUER | 64,570 sh |
GOYAL ARJUN Director Jun 24, 2026 | TO ISSUER | 462,585 sh |
Kulkarni Samarth Director Jun 24, 2026 | TO ISSUER | 208,474 sh |
Hukkelhoven Mathias Director Jun 24, 2026 | TO ISSUER | 96,000 sh |
Weinhoff Gregory M Chief Business Officer Jun 24, 2026 | TO ISSUER | 584,321 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next FY | -$1.78 | -$2.06–-$1.30 | +6.2% | $28.6M |
| Next Q | -$0.39 | -$0.39–-$0.39 | +11.0% | $0.00 |
| Current Q | -$0.39 | -$0.39–-$0.39 | +8.0% | $0.00 |
| Current FY | -$1.56 | -$1.56–-$1.56 | +0.0% | $0.00 |
Short side
FINRA· Jun 15, 2026SecBot reports
5 filings · 2 bullish · 3 bearish- BEARISH 15-12GJul 6, 2026
Centessa Pharmaceuticals filed a Form 15-12G on July 6, 2026, to voluntarily deregister its…
Shares will move to the OTC or cease trading entirely as the company goes dark. Given only 5 holders of record, this is a definitive end to public market participation, any remaining CNTA equity is…
- BULLISH PREM14AApr 17, 2026
Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured…
Investors should vote their shares by the deadlines to ensure the transaction proceeds. The stock is likely to trade close to the $38.00 offer price until closing. Monitor for any competing bids or…
- BULLISH DEFA14AApr 13, 2026
Centessa Pharmaceuticals is soliciting shareholder approval for its acquisition by Eli Lilly…
Traders should monitor for the definitive proxy statement and upcoming shareholder vote, which will confirm deal momentum. Absent competing bids or regulatory hurdles, the acquisition is likely to…
- BEARISH CLUSTERMar 13, 2026
Centessa Pharmaceuticals C-suite executives sold over $7.2M in stock within a week, primarily from…
Monitor for upcoming earnings or pipeline updates; such concentrated C-suite selling often precedes negative news or reflects valuation concerns. Watch for follow-on selling or lack of buybacks.
All CNTA filing & press-release reports (5)
- 15-12G reportJul 6, 2026
- PREM14A reportApr 17, 2026
- DEFA14A reportApr 13, 2026
- CLUSTER reportMar 13, 2026
- CLUSTER reportMar 13, 2026